Clinical research on biomarker panels of ovarian cancer based on peptide array technology

Clinical research on the array for ovarian cancer antibodies

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200056873

Enrollment

Unknown

Registered

2022-02-22

Start date

2019-02-27

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

Gold Standard:Pathological clinical diagnosis results

Index test:Compare the performance of biomarker panels and CA125 in the diagnosis and outcome prediction of ovarian cancer, including sensitivity, specificity, etc.

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Women aged >18 years; 2. Suspected ovarian cancer patients; 3. Agree to participate in the clinical trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. History of bilateral ovariectomy; 2. Had an organ transplant; 3. No specimen was taken.

Design outcomes

Primary

Measure	Time frame
Sensitivity;Specificity;	—

Countries

China

Contacts

Public ContactYue Wentao

yuewt2000@yahoo.com+86 10 52277678

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026